FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC
FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC
Not yet recruiting · NCT07729605 · Registry updated 2026-07-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRC | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Spinocerebellar Degenerations, brain disorder, central nervous system disorder, cerebellar disorder, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, hereditary disease, inherited neurodegenerative disorder, intestinal disorder, neoplasm, nervous system disorder, neurodegenerative disease, rectal disorder, spinal cord disorder | Not yet recruiting | Phase 3 | 2026-07-27 | NCT07729605 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Sun Yat-sen University | 606 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The Sixth Affiliated Hospital of Sun Yat-sen University | Guangzhou | China | 9 |